Cangrelor

Generic Name: Cangrelor

Brand Names: Kengreal, Kengrexal

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₅Cl_₂F_₃N_₅O_₁₂P_₃S_₂

CAS Number: 163706-06-7

Unique Ingredient Identifier: 6AQ1Y404U7

Background: Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.

Indication: For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Associated Conditions: Coronary Revascularization, Peri-procedural Myocardial Infarction, Thrombosis (Stent Thrombosis)

Associated Therapies: -

Clinical Trials

Platelet Inhibition to Target Reperfusion Injury

Phase 2

Conditions: STEMI

Interventions: Drug: Cangrelor

First Posted Date: 2017-04-06

Last Posted Date: 2022-04-26

Lead Sponsor: National Heart Centre Singapore

Target Recruit Count: 228

Registration Number: NCT03102723

Locations: 🇸🇬
National University Hospital (NUH), Singapore, Singapore
🇸🇬
Khoo Teck Puat Hospital, Singapore, Singapore
🇸🇬
Changi General Hospital, Singapore, Singapore

and more 2 locations

Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Terminated

Conditions: Non-ST Elevation Myocardial Infarction (NSTEMI)

Interventions: Drug: Tirofiban
Drug: Cangrelor

First Posted Date: 2017-02-09

Last Posted Date: 2023-12-11

Lead Sponsor: Inova Health Care Services

Target Recruit Count: 10

Registration Number: NCT03048019

Locations: 🇺🇸
Inova Health Care System, Falls Church, Virginia, United States

Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size

Phase 4

Terminated

Conditions: STEMI - ST Elevation Myocardial Infarction

Interventions: Drug: Cangrelor

First Posted Date: 2017-02-06

Last Posted Date: 2020-06-30

Lead Sponsor: Khaled Ziada, MD

Target Recruit Count: 23

Registration Number: NCT03043274

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Phase 4

Completed

Conditions: STEMI - ST Elevation Myocardial Infarction
Coronary Artery Disease

Interventions: Drug: Cangrelor
Drug: Tirofiban
Drug: Prasugrel

First Posted Date: 2016-11-30

Last Posted Date: 2020-02-21

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 122

Registration Number: NCT02978040

Locations: 🇨🇭
Bern University Hospital, Bern, Switzerland
🇮🇹
University of Ferrara, Ferrara, Italy
🇮🇹
University of Naples Federico II, Naples, Italy

Cangrelor Neonatal PK/PD and Safety Study

Phase 1

Completed

Conditions: Partial Obstruction of Systemic to Pulmonary Artery Shunt
Complete Obstruction of Systemic to Pulmonary Artery Shunt

Interventions: Drug: Cangrelor

First Posted Date: 2016-05-06

Last Posted Date: 2023-02-15

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 22

Registration Number: NCT02765633

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States